Fonkogem 200mg powder for injection

Ferron Par Pharmaceuticals

Ingredients in every vial

Gemcitabine HCl 200 mg

Each package contains

1 vial of 200 mg

Other details

Dosage form:Powder for injection
Flavour None

W.H.O. classification

ATC Level 1 L - Antineoplastic and immunomodulating agents
ATC Level 2 L01 - Antineoplastic Agents
ATC Level 3 L01B - Antimetabolites

Warnings

Pregnancy

NOT SAFEThis item is not safe for use during pregnancy.

Lactation

NOT SAFEThis item is not safe for use during lactation.

Alcohol

NOT SAFEThis item should not be used with alcohol.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Available in

Indonesia
Cambodia

Dosage information

18 YEARS OLD AND ABOVE
Single-agent use:
Pancreatic cancer: gemcitabine should be administered by intravenous infusion at a dose of 1,000 mg/m2 over 30 minutes once weekly for up to 7 weeks, followed by a week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks.
Dose modifications: dosage adjustment is based upon the degree of hematologic toxicity experienced by the patient.
Combination use :
Non-small cell lung cancer: two schedules have been investigated and the optimum schedule has not been determined. With the 4-weeks schedule, gemcitabine should be administered intravenously at 1,000 mg/m2 over 30 minutes on days 1, 8, and 15 of each 28-day cycle. With the 3-weeks schedule, gemcitabine should be administered intravenously at 1,250 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle. Cisplatin has been used at doses between 75-100 mg/m2 after administration of gemcitabine on day 1 of each 21-day or 28-day cycle. Dosage reduction with each cycle or within a cycle may be applied based upon the amount of toxicity experienced by the patients.
Breast cancer: gemcitabine should be administered intravenously at a dose of 1,250 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle. Paclitaxel should be administered at 175 mg/m2 on day 1 as a 3 hours intravenous infusion before gemcitabine administration. Patients should be monitored prior to each dose with a complete blood count, including differential counts. Patient should have an absolute granulocyte count 1,500 x 106/l and a platelet count >100,000 x 106/l prior to each cycle. Dosage reduction with each cycle or within a cycle may be applied based upon the amount of toxicity experienced by the patient.
Ovarian cancer: gemcitabine should be administered intravenously at a dose of 1,000 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle. Carboplatin (at the dose required to obtain an AUC of 4 mg/ml) should be administered intravenously on day 1 after gemcitabine administration. Dosage reduction with each cycle or within a cycle may be applied based upon the amount of toxicity.

65 YEARS OLD AND ABOVE
Elderly patients
Gemcitabine clearance and half-life are affected by age

HEPATIC AND RENAL IMPAIRMENT
Gemcitabine should be used with caution in patients with hepatic insufficiency or with impaired renal function as there is insufficient information to allow clear dose recommendation for this patient population.

Indication

– Ovarian cancer
Gemcitabine in combination with carboplatin indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed following platinum-based therapy.
– Breast cancer
Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer who have relapsed following adjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
– Non-small cell lung cell
Gemcitabine is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (stage IIIA or IIIB) or metastatic (stage IV) non-small cell lung cancer.
– Pancreatic cancer
Gemcitabine is indicated as first-line treatment for patients with locally advanced (non-resectable stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with 5-FU